HIV Clinical Trials - Global Strategic Business Report 2026-2032 Featuring Strategic Intelligence on Gilead, ViiV Healthcare, Merck, and Pfizer

Résumé détaillé
Dublin, Nov. (GLOBE NEWSWIRE) -- "HIV Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering. The global HIV clinical trials…
Dublin, Nov. 20, 2026 (GLOBE NEWSWIRE) -- "HIV Clinical Trials - Global Strategic Business Report 2026" has been added to ResearchAndMarkets.com's offering.
The global HIV clinical trials market was valued at US$1.5 billion in 2025 and is projected to reach US$2.1 billion by 2032, expanding at a compound annual growth rate (CAGR) of 4.8%. Market growth is supported by sustained investment in HIV research, increased development of long-acting antiretroviral therapies, expanding vaccine pipelines, and the adoption of advanced technologies across clinical research.
Researchers are advancing long-acting antiretrovirals, functional cure strategies, preventive vaccines, combination therapies, and antibody-based treatments. Pharmaceutical and biopharmaceutical companies, governments, academic institutions, and nonprofit organizations are investing in treatment regimens designed to improve adherence, strengthen viral suppression, address drug resistance, and reduce adverse effects.
Injectable and implantable antiretroviral therapies are reshaping clinical development by offering alternatives to daily oral medication. Pre-exposure prophylaxis, broadly neutralizing antibodies, nanomedicine, and personalized treatment strategies are also gaining prominence as clinical programs pursue more durable and targeted approaches to HIV treatment and prevention.
Artificial intelligence, genomic sequencing, CRISPR-based gene editing, digital health platforms, and predictive analytics are transforming HIV clinical trial design and execution. Artificial intelligence supports patient recruitment, biomarker identification, protocol optimization, and predictive modeling. Gene-editing research is investigating long-term viral suppression and the potential elimination of persistent HIV reservoirs.
mRNA vaccine platforms have also created new opportunities for preventive HIV vaccine research. Meanwhile, decentralized and virtual clinical trial models-including telemedicine, remote monitoring, and…
Pub…
Début de l'article, extrait de Yahoo Finance. Pour lire la suite, ouvrez l'article chez le média.
MarketNews présente le titre et le résumé publiés par le média. L'article complet se lit sur le site de l'éditeur. (finance.yahoo.com)




